Shares of Pfenex Inc (NYSE: PFNX), engaged in the development of biosimilar therapeutics, recorded over 21.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. PFNX was among the top performers in U.S. healthcare sector after gaining 24.7% and closed at $12.16 Thursday, while recording significant trading volumes of 1.1 million shares. Recently, PFNX announced that it has entered into an agreement with Hospira, Inc., (NYSE: HSP) to exclusively develop and commercialize for worldwide sales PF582, Pfenex’s biosimilar candidate to Genentech’s LUCENTIS®. During the past 5-trading sessions, PFNX gained 81.5% with daily average trading volumes of 745,831 shares, while the stock accumulated 71.5% gain during the past one month with daily average trading volumes of 165,525 shares. The stock is up 69.4% year-to-date.
Company Description:
Pfenex Inc. (NYSE: PFNX) provides clinical-stage biotechnology products. The company offers high-value proteins and biosimilar therapeutics. Pfenex serves customers in the United States.
1-Year Stock Chart:
Source: Bloomberg
